HONG KONG, April 7, 2022 /PRNewswire/ — SIMCERE PHARMA (HK.2096), an innovation and R&D-driven pharmaceutical company with a mission of “providing today’s patients with medicines of the future”, will host a virtual R&D Day, on Friday, 15 April, 2022, at 21:00-23:00 (HKT) / 9:00-11:00 (EST) / 13:00-15:00 (GMT).
The R&D Day will feature presentations from Mr. Ren Jinsheng(Chairman of the Board & CEO), Mr. Zhou Gaobo(CIO), Dr. Tang Renhong(EVP), Dr. Bijoyesh Mookerjee(CMO), Dr. Danny Chen(SVP) and Dr. Kevin Oliver(SVP).
A live question and answer session will follow. To register for the event, please click here (https://www.simcere.com/xs2022/).
For further information, please contact:
Jason Bao, The Secretary of the Board
E-mail: ir@simcere.com
About Simcere
Simcere Pharmaceutical Group is an innovation and R&D-driven pharmaceutical company. It has established a National Key Laboratory of Translational Medicine and Innovative Drug Development. The company focuses on three therapeutic areas, oncology, central nervous system, and autoimmune diseases, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of “providing today’s patients with medicines of the future.” Bases on its R&D and commercialization excellence, Simcere is in a leading position for its main products in the Chinese market. Its vigorous in-house R&D efforts and extensive R&D collaborations have made it a strategic cooperation partner with world leading innovative companies and research institutes.
Support Independent Community Journalism
Dear Reader,The Indian Sun exists for one reason: to tell stories that might otherwise go unheard.
We report on local councils, state politics, small businesses and cultural festivals. We focus on the Indian diaspora and the wider multicultural community with care, balance and accountability. We publish in print and online, send regular newsletters and produce video content. We also run media training programs to help community organisations share their own stories.
We operate independently.
Community journalism does not have the backing of large media corporations. Advertising revenue fluctuates. Platform algorithms change. Costs continue to rise. Yet the need for credible, grounded reporting in a multicultural Australia has never been greater.
When you support The Indian Sun, you support:
• Independent reporting on issues affecting migrant communities
• Coverage of local and state decisions that shape daily life
• A platform for small businesses and community groups
• Media training that builds skills within the community
• Journalism accountable to readers
We cannot cover everything, but we work to cover what matters.
If you value thoughtful reporting that reflects Australia’s diversity, we invite you to contribute. Every donation helps us maintain the quality and consistency of our work.
Please consider making a contribution today.
Thank you for your support.
The Indian Sun Team
